Rafferty Asset Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Rafferty Asset Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-5,775	Closed	-$277K	–	1018
2020 Q1	$277K	Sell	5,775 -43,220	-88%	-$2.01M	0.01%	459
2019 Q4	$2.3M	Sell	48,995 -48,988	-50%	-$2.17M	0.04%	342
2019 Q3	$2.32M	Buy	97,983 +22,891	+30%	+$678K	0.04%	310
2019 Q2	$2.26M	Buy	75,092 +31,696	+73%	+$726K	0.04%	365
2019 Q1	$972K	Buy	+43,396	New	+$933K	0.02%	556

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Rafferty Asset Management's RARX Position: Q2 2020 in Review

Rafferty Asset Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 5,775 shares — an estimated $277K sold.

Rafferty Asset Management first reported a position in RARX in Q1 2019 and held it in 5 quarters. The position peaked at $2.32M in Q3 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Rafferty Asset Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Rafferty Asset Management sold 5,775 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $277K.
Rafferty Asset Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 5 quarters.
Rafferty Asset Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $2.32M in Q3 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Rafferty Asset Management's 13F filing for Q2 2020, filed 7 Aug 2020.